Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4916 · 1 trial · 1 indication
The safety and tolerability of AZD4916 following oral administration of single-ascending doses and multiple-ascending doses to healthy participants (including Japanese and Chinese) will be assessed.
| Arm | Type | Description |
|---|---|---|
| AZD4916 | EXPERIMENTAL | Parts 1a and 2a participants will receive a single oral dose of AZD4916 on Day 1. Parts 1b and 2b participants will receive a single oral dose of AZD4916 on Day 1 and multiple doses of AZD4916 on Days 4 through 17. |
| Placebo | PLACEBO_COMPARATOR | Parts 1a and 2a participants will receive a single oral dose of placebo on Day 1. Parts 1b and 2b participants will receive a single dose placebo on Day 1 and multiple doses of placebo on Days 4 through 17. |
| Name | Type | Description |
|---|---|---|
| AZD4916 | DRUG | AZD4916 will be administered as oral solution. |
| Placebo | OTHER | Placebo will be administered as oral solution. |
Main Inclusion Criteria: * Healthy male and female participants with suitable veins for cannulation or repeated venipuncture. * All females must have negative pregnancy test and females of childbearing potential must not be lactating and must agree to use an approved method of highly effective cont...
AZD4916 is an investigational small molecule drug being developed by AstraZeneca PLC. It is currently in Phase 1 clinical development, with one active trial evaluating it in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
AZD4916 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the Phase 1 clinical program for this investigational small molecule.
AZD4916 is in Phase 1 clinical development. It has one active, recruiting Phase 1 trial and no completed trials. As an investigational drug, it has not been approved by the FDA and remains in early-stage clinical testing.
AZD4916 is being studied in one Phase 1 trial, NCT06951880, titled a study to investigate the safety and pharmacokinetics of single- and multiple-ascending doses of AZD4916 in healthy volunteers. The trial is recruiting, is placebo-controlled and randomized, and plans to enroll 160 participants in the United States and United Kingdom.
The Phase 1 trial NCT06951880 enrolls healthy adult volunteers aged 18 years and older, with no restriction by sex. It is a randomized, placebo-controlled study of single- and multiple-ascending doses, conducted at sites in the United States and the United Kingdom, with a planned enrollment of 160 participants.